Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Q3 FY2025 Earnings Presentation
19 slides from Little Green Pharma's earnings presentation, May 13, 2025
Slide 1: March 2025 Quarterly & Appendix 4C
March 2025 Quarterly & Appendix 4C ASX:LGP For personal use only Investor presentation MARCH 2025 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
2 Disclaimer Disclaimer Not financial product advice For personal use only This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, activi
Slide 3: Little Green Pharma
Little Green Pharma For personal use only 30t 5 BRANDS 31 PRODUCTS 4 FACILITIES PRODUCTION CAPACITY 11 13 SPONSORED 94 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK
Slide 4: Revenue and cash receipts
REVENUE & CASH RECEIPTS Revenue and cash receipts For personal use only LGP FY25 revenue of $36.6 million (unaudited) representing over 40% growth from prior year, with Health House generating further $0.8 million in third party product sales in two months post acquisition LGP revenue of $9.6 millio
Slide 5: Revenue by product category
REVENUE BY PRODUCT CATEGORY LGP revenue by product category ($000’s)* 12,000 Revenue by 10,000 product category 8,000 For personal use only 6,000 4,000 Flower sales increased by over 10% predominantly driven by 115% 2,000 increase in flower sales in Europe 0 offset by 10% reduction in flower FY24Q4
Slide 6: Revenue by segment
REVENUE BY SEGMENT LGP revenue by segment ($000’s)* 12,000 Revenue by 10,000 segment 8,000 For personal use only 6,000 4,000 European sales up nearly 50% 2,000 driven by 115% increase in - flower sales into Germany and FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 the United Kingdom offset by Australia Europe
Slide 7: Revenue by brand
REVENUE BY BRAND Revenue by brand LGP revenue by brand ($000’s)* For personal use only 12,000 White label sales up 105% driven by significant growth in flower sales into 10,000 Germany and the United Kingdom CherryCo sales up 10% on prior 8,000 quarter with stock on hand now at appropriate levels 6,
Slide 8: Net cashflows from operations
NET CASHFLOWS FROM OPERATIONS Net operating cash outflows of $0.8 million driven by settlement of certain historical Health House liabilities combined with LGP’s working capital and inventory requirements to meet increased Net cashflows demand along with record March sales for which receipts will be
Slide 9: EV, NTA, cash, debt and revenue
EV, NTA, CASH, DEBT AND REVENUE EV, NTA, cash, EV, NTA, cash, debt & annualised revenue ($000’s) debt and revenue For personal use only 100,000 100,000 Company’s net tangible assets continue to significantly exceed 80,000 80,000 enterprise value 60,000 60,000 Minimal long-term debt of $3.1 million w
Slide 10: Market update: Strong market growth globally (Germany)
MARKET UPDATE Strong market growth globally For personal use only Germany Cannabis flower imports Legalisation helped drive ~72 tonnes of imports across CY24, of which 31.7 tonnes was imported in CY24Q4 alone, a record quarterly result and up 53% on CY24Q31 By way of comparison, legalised cannabis c
Slide 11: Market update: France
MARKET UPDATE Strong market growth globally (cont.) For personal use only France France’s Health Ministry submitted three draft decrees to the European Commission covering cultivation, product authorisation and quality standards in late March 2025 Transition period extended to 31 March 2026 ensuring
Slide 12: Market update: Spain
MARKET UPDATE Strong market growth globally (cont.) For personal use only Spain Spain’s Royal Decree submitted to European Commission on 23 January 2025 Spanish Government intends to approve the Royal Decree by mid CY25. Product monographs may be released by Spanish Medicines Agency within 3 months
Slide 13: Health House update
HEALTH HOUSE update For personal use only Successful acquisition of Health House medicinal cannabis distribution business on 1 February 2025 Integration currently underway and ahead of schedule Majority of Health House customers retained validating strategic fit Health House complements LGP’s strate
Slide 14: Brand & product update
BRAND & PRODUCT UPDATE Brand & product For personal use only update Company shortlisted for Cannabiz Awards 2025 for Company of the Year, Business Leader of the Year, Best Place to Work, and Best Education or Engagement Initiative, with results to be announced in late May 2025 Company to launch a ne
Slide 15: Research & innovation update
RESEARCH & INNOVATION update For personal use only 12-month QUEST Study results published in peer- reviewed journal PLOS One Study finds long-term efficacy of LGP medicinal cannabis for various chronic conditions Follow-up results from 2,353 patients show: • clinically meaningful improvements across
Slide 16: RESET update
RESET UPDATE update For personal use only First patient completed both treatment arms and 12-month follow-up Clinical outcomes favourable; formal results expected mid-2026 Department of Veterans Affairs confirms it will fund MDMA and Psilocybin assisted therapies for veterans with post-traumatic str
Slide 17: Corporate overview
CORPORATE OVERVIEW Corporate overview For personal use only Capital structure Shareholder structure Current share price1 $0.115 Shares outstanding1 ~304 million Options and performance rights on Issue2 ~24 million 24% Market capitalisation (undiluted) ~$35 million 37% Cash reserves (31 March 2025) ~
Slide 18: The next months: Delivering on strategy
THE NEXT 6 MONTHS Delivering on strategy For personal use only Development of Health House business including implementation of synergies and cost savings Continue to meet rapidly growing Germany & UK flower supply through expanded facilities and launch CherryCo brand in June at Mary Jane conference
Slide 19: Q&A
For personal use only Q&A Paul Long, Managing Director A world of difference investor.littlegreenpharma.com
Little Green Pharma — Q3 FY2025 Earnings Presentation on 6ix